Physician profile
Victor E Lambert
NPI 1154317790
$1,564.25
in general payments reported to CMS, 2019-2025
14 companies · $318 in 2025
The $318 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $139 · 2020: $112 · 2021: $303 · 2022: $172 · 2023: $333 · 2024: $187 · 2025: $318.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $837 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $836.94 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $738.43 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $189.60 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Novartis Pharmaceuticals Corporation | $189.25 | 2019-2023 | |
| Pfizer INC. | $102.57 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.84 | 2020-2024 | Jardiance |
| Exact Sciences Corporation | $57.53 | 2025 | The Cologuard Plus Collection Kit |
| Otsuka America Pharmaceutical, INC. | $52.49 | 2022-2023 | Rexulti |
| Amgen INC. | $38.00 | 2024 | Repatha |
| Astrazeneca Pharmaceuticals LP | $32.64 | 2023 | Breztri, Farxiga |
| Astellas Pharma US INC | $24.17 | 2019 | |
| Abbott Laboratories | $23.01 | 2021 | |
| Eisai INC. | $18.95 | 2021 | |
| Merck Sharp & Dohme LLC | $10.98 | 2020 | |
| Sumitomo Pharma America, INC. | $0.79 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victor Lambert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.